Weili Zhao
Ruijin Hospital
11
7
2
N/A
0
5
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+21 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (11)
Showing 10 of 11 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Xiangyu Zhao
Peking University People's Hospital
Shared therapeutic areas:
Worked with same sponsors:
Hagop Youssoufian, MD
Verastem, Inc.
Shared therapeutic areas:
Qifa Liu
Nanfang Hospital, Southern Medical University
Shared therapeutic areas:
Worked with same sponsors:
Mary Horowitz, MD
Center for International Blood and Marrow Transplant Research
Shared therapeutic areas:
Arnon Nagler, MD
Chaim Sheba Medical Center
Shared therapeutic areas:
Hongmei Jing
Peking University Third Hospital
Shared therapeutic areas:
Worked with same sponsors:
Mitchell Cairo, MD
New York Medical College
Shared therapeutic areas:
Beata Holkova, MD
Massey Cancer Center
Shared therapeutic areas:
Jae Park, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Roberto Hernández Martín, MD
Hospital Virgen de la Concha
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (11)
Showing 11 of 11 trials
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy
Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study
CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy
Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.
All 11 trials loaded